Tenofovir-based combination therapy for HIV/HBV co-infection: factors associated with a partial HBV virological response in patients with undetectable HIV viraemia

The aim of this study was to identify and describe patients with detectable hepatitis B virus (HBV) DNA in the presence of undetectable HIV RNA after 48 weeks of tenofovir disoproxil fumarate (TDF)/emtricitabine (FTC) or lamivudine (3TC) treatment. Case-control study. Cases or delayed responders wer...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	AIDS (London) 2013-06, Vol.27 (9), p.1443-1448
Hauptverfasser:	CHILDS, Kate, JOSHI, Deepak, BYRNE, Ruth, BRUCE, Matthew, CAREY, Ivana, AGARWAL, Kosh, TAYLOR, Chris
Format:	Artikel
Sprache:	eng
Schlagworte:	Adenine - analogs & derivatives Adenine - therapeutic use Adult AIDS/HIV Anti-HIV Agents - therapeutic use Antibiotics. Antiinfectious agents. Antiparasitic agents Antiviral agents Biological and medical sciences Case-Control Studies Coinfection Deoxycytidine - analogs & derivatives Deoxycytidine - therapeutic use DNA, Viral - genetics Drug Resistance, Viral - genetics Drug Therapy, Combination Emtricitabine Hepatitis B virus Hepatitis B virus - genetics Hepatitis B, Chronic - complications Hepatitis B, Chronic - diagnosis Hepatitis B, Chronic - drug therapy HIV Infections - complications HIV Infections - diagnosis HIV Infections - drug therapy Human immunodeficiency virus Human viral diseases Humans Infectious diseases Lamivudine - therapeutic use Medical sciences Pharmacology. Drug treatments Phosphorous Acids - therapeutic use Viral diseases Viral diseases of the lymphoid tissue and the blood. Aids Viral hepatitis Viremia - diagnosis Viremia - drug therapy
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	The aim of this study was to identify and describe patients with detectable hepatitis B virus (HBV) DNA in the presence of undetectable HIV RNA after 48 weeks of tenofovir disoproxil fumarate (TDF)/emtricitabine (FTC) or lamivudine (3TC) treatment. Case-control study. Cases or delayed responders were defined as detectable HBV DNA (>20 IU/ml) with undetectable HIV RNA (
ISSN:	0269-9370 1473-5571
DOI:	10.1097/QAD.0b013e32836011c2